The study is researching an investigational drug called ALN-HSD (called "study drug" in this form). The study is focused on participants who are known to have non-alcoholic steatohepatitis (NASH). NASH is a form of non-alcoholic fatty liver disease (NAFLD). NASH occurs when fat builds up in liver cells, damaging them, and making the liver inflamed and stiff from fibrosis (scar tissue). NASH can progress to cirrhosis (long term scarring) and liver failure (when your liver cannot perform its job). The aim of the study is to see the effect of the study drug on lessening liver scarring side effects related to NASH.The study is looking at several other research questions, including:How ALN-HSD works to improve liver function and lessen NASH related inflammation in the liverWhat side effects may happen from receiving the study drugHow much study drug and study drug metabolites (byproduct of the body breaking down the study drug) are in your blood at different timesBetter understanding of the study drug and NASH

The goal of this study:Estimate complete remission (CR) rate per the Lugano classification with a combination of epcoritamab and GDP in subjects with relapsed large cell lymphoma.Estimate overall response rate (ORR) per the Lugano classification with a combination of epcoritamab and GDP in subjects with relapsed large cell lymphoma.Estimate duration of response (DOR) with a combination of epcoritamab and GDP in subjects with relapsed large cell lymphoma.Estimate progression free survival (PFS) with a combination of epcoritamab and GDP in subjects with relapsed large cell lymphoma.Estimate overall survival (OS) with a combination of epcoritamab and GDP in subjects with relapsed large cell lymphoma.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

WHY IS THIS STUDY BEING DONE?Autoimmune hepatitis (AIH) is liver inflammation that occurs when the body’s immune system attacks liver cells. It is caused by an overactive immune system, and it is unknown why this happens. The Autoimmune Hepatitis Association (AIHA) is a not-for-profit organization seeking to develop a patient registry for people who are affected by autoimmune hepatitis to begin to characterize this poorly understood disease. 

 Placental chorangioma is a rare pregnancy complication but with significant maternal and fetal consequences. Chorangioma is a benign tumor of the placenta. As it grows, it can cause pregnancy complications. Little is known about the natural history of placental chorangioma or its response to in-utero intervention. The aim of this research is to describe outcomes in pregnancies complicated by placental chorangiomas. There are no procedures or interventions done to the mother or baby as part of this research.